Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  • Equipment

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  • Equipment
  1. Outputs

[Early access programs and managed entry agreements for medicines in Italy: results of a Focus Group (Early Access Programs and Managed Entry Agreement).]

Academic Article
Publication Date:
2021
Short description:
[Early access programs and managed entry agreements for medicines in Italy: results of a Focus Group (Early Access Programs and Managed Entry Agreement).] / Jommi, C., Armeni, P., Costa, F., Alberti, C., Bandello, F., Bordonaro, R., Caprodossi, A., Di Maio, M., Gaudioso, A., Giuliani, G., Langella, R., Marata, A.M., Patarnello, F., Pinto, C., Rasi, G., Villa, F.. - In: RECENTI PROGRESSI IN MEDICINA. - ISSN 2038-1840. - 112:11(2021), pp. 749-756. [10.1701/3696.36853]
abstract:
Background: Early access of medicines occurs with an uncertainty in the evidence even higher than the one experienced when price and reimbursement status is negotiated. Our aim is discussing the role of managed entry agreements (MEA) within early access programs (EAP) in Italy. Methods: The discussion relied on a Focus Group, participated by twelve experts, including clinicians and representatives of regulatory authorities, regional and local pharmaceutical departments, pharmaceutical companies, and an association advocating for active citizenship. Results: The Focus Group emphasised that the topic under discussion should be embedded into a more general reform of EAP in Italy. The 648 List mostly includes mature products and indications that are rarely launched into the market afterwards. The 5% Fund is affected by an important administrative burden uncertainty of the timing of reimbursement. Conclusions: Starting from the discussion on MEA and EAP, the Focus Group recommended a new legislation better regulating EAP, that early access concerns specific classes of medicines selected on the grounds of the need to guarantee a rapid access and to collect real world data, that early access can be accompanied by outcome-based and population-based MEA, and that MEA are embedded into the subsequent price and reimbursement negotiation.
Iris type:
1.1 Articolo in rivista
List of contributors:
Jommi, Claudio; Armeni, Patrizio; Costa, Francesco; Alberti, Chiara; Bandello, Francesco; Bordonaro, Roberto; Caprodossi, Andrea; Di Maio, Massimo; Gaudioso, Antonio; Giuliani, Giovanni; Langella, Roberto; Marata, Anna Maria; Patarnello, Francesca; Pinto, Carmine; Rasi, Guido; Villa, Federico
Handle:
https://iris.unisr.it/handle/20.500.11768/149199
Published in:
RECENTI PROGRESSI IN MEDICINA
Journal
  • Overview

Overview

URL

https://www.recentiprogressi.it/archivio/3696/articoli/36853/
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.10.1.0